Company Information

  

Address: 3 FORBES ROAD  
City: LEXINGTON 
State: MA 
Zip Code: 02421 
Telephone: 781-674-4410 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

We are a clinical-stage immuno-oncology ("I-O") company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. Our business is designed to drive success in I-O through speed, innovation, and effective combination therapies. We have assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice ("GMP") manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. We leverage our immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance our innovation.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-1.58NAN/E
12/2017-1.23NAN/E
09/2017-1.18NAN/E
06/2017-1.28NAN/E
03/2017-1.27NAN/E
12/2016-1.46NAN/E
09/2016-1.34NAN/E
06/2016-0.99NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.13Total Liab/Total Assets1.55
Net Inc/Total Assets-0.87Total Liab/Inv Cap3.49
Net Inc/Inv Cap-1.97Total Liab/Comm Equity0.22
Pretax Inc/Net Sales-2.81Interest Coverage Ratio-5.40
Net Inc/Net Sales-2.81Curr Debt/Equity-0.27
Cash Flow/Net Sales-2.20LTD/Equity-1.88
SG&A/NetSales0.71Total Debt/Equity-2.15
Asset Utilization   Liquidity  
Net Receivables Turnover6.87Quick Ratio1.30
Inventory TurnoverNACurrent Ratio1.30
Inventory Day SalesNANet Rec/Curr Assets0.02
Net Sales/Work Cap2.51Inv/Curr Assets0.00
Net Sales/PP&E1.64  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 1.64 8.35 3.36 4.21
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 13.94 6.47 9.23 7.27
Operating Income -41.75 -29.99 -31.66 -28.89
Interest Exp 2.78 5.10 4.70 4.47
Pretax Income -43.49 -35.03 -36.84 -31.71
Other Income -9.73 0.06 -0.47 1.65
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -54.14 -35.03 -36.84 -31.71

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 52.35 60.19 70.05 96.77
Receivables - Total 1.13 1.13 2.19 3.94
Inventories - Total 0.06 0.08 0.08 0.09
Total Current Assets 65.19 73.55 84.34 110.69
Net Property, Plant & Equipment 27.04 26.18 25.64 25.58
Total Assets 130.82 138.40 149.27 176.49
Liabilities        
Accounts Payable 23.46 29.66 27.28 25.14
Debt in Current Liabilities 0.15 20.64 19.96 0.15
Total Current Liabilities 30.16 56.44 54.41 32.91
Long-Term Debt 12.77 142.39 123.29 138.53
Total Liabilities 244.20 214.22 200.86 193.97
Stockholder's Equity        
Minority Interest 0.15 NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 1.03 1.02 1.00 1.00
Retained Earnings -1,071.76 -1,026.48 -991.44 -954.60
Treasury Stock NA NA NA NA
Total Stockholders' Equity -113.39 -75.82 -51.59 -17.48
Total Liabilities and Stockholders' Equity 130.82 138.40 149.27 176.49

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -40.25 -25.87 -26.15 -27.38
Net Cash Provided by Investing Activities -1.49 4.25 9.04 -5.96
Net Cash Provided by Financing Activities 33.79 16.77 0.41 1.29

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20133.05-30.07-1.12
12/20146.98-42.49-0.71
12/201524.82-87.88-1.13
12/201622.57-127.00-1.46
12/201742.88-120.69-1.23
Growth Rates93.71----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/1813147,28045.46




Report Date : 7/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.